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ABSTRACT 
 
Rapid advances in nanotechnology necessitate assessment of the safety of nanomaterials 
in the resulting products and applications. One key nanomaterial attracting much interest in many 
areas of science and technology is graphene. Graphene is a one atom thick carbon allotrope 
arranged in a two-dimensional honeycomb lattice. In addition to being extremely thin, graphene 
has several extraordinary physical properties such as its exceptional mechanical strength, thermal 
stability, and high electrical conductivity. Graphene itself is relatively chemically inert and 
therefore pristine graphene must undergo a process called functionalization, which is 
combination of chemical and physical treatments that change the properties of graphene, to make 
it chemically active. Functionalization of graphene is of crucial importance as the end application 
of graphene depends on proper functionalization. In the field of medicine, graphene is currently a 
nanomaterial of high interest for building biosensors, DNA transistors, and probes for cancer 
detection. Despite the promising applications of graphene in several areas of biomedicine, there 
have been only few studies in recent years that focus on evaluating cytotoxicity of graphene on 
cells, and almost no studies that investigate how graphene exposure affects cellular genetic 
material. Therefore, in this study we used a novel approach to evaluate the genotoxicity, i.e., the 
effects of graphene on DNA, using Escherichia coli as a prokaryotic model organism. 
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INTRODUCTION 
 Graphene is a one-atom-thick planar sheet consisting of sp2 carbon atoms that are 
densely packed in a honeycomb crystal lattice. Graphene has many unique properties such as 
high surface area, high electrical conductivity, high thermal conductivity and high optical 
transmittance. Due to these unique chemical and structural properties, graphene has been 
attracting interest in several commercial fields. Specifically, in the field of medicine, graphene is 
currently a nanomaterial of interest for building biosensors, DNA transistor and even biosensor 
for cancer detection (Sun et al. 2008; Park et al. 2009; Shao et al. 2010; Feng and Liu 2011; 
Kuila et al. 2012; Wang et al. 2012; Chung et al. 2013; Liu et al. 2013; Chabot et al. 2014).  
Even though scientists had theorized graphene since the 1980s it was produced and 
isolated in the lab for the first time in 2004. Andre Geim and Konstantin Novoselov, at the 
University of Manchester were the first ones to isolate pristine graphene from graphite and their 
contribution towards the isolation and characterization of graphene (Novoselov et al. 2005) won 
them the Nobel Prize in Physics in 2010. Pristine graphene, which is composed of only sp2 
carbon atoms, is a zero-gap semiconductor which is why it is chemically inert and needs to be 
functionalized in order for graphene to have the desired chemical and physical attributes to be 
used in the development of graphene based devices.  
 Functionalization of graphene is one of the key topics in graphene research (Georgakilas 
et al. 2012, Kulia et al. 2012; Chabot et al. 2014). Generally, there are two main categories of 
functionalization: chemical and nonchemical. Chemical functionalization is carried out through 
the formation of new covalent bonds between the atoms native to graphene and different 
functional groups (such as -O, –COOH, and -OH). In contrast, nonchemical functionalization is 
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mainly based on non-covalent interaction between functional molecules and graphene. Both 
types of functionalization change the properties of pristine graphene, but the chemical routes are 
more effective (Hu and Sun 2008). However, the addition of certain chemical groups to graphene 
has been shown to cause oxidative stress and toxicity in bacterial cells (Akhavan 2010; Sanchez 
2011; Yue et al. 2012; Yang et al. 2013). Hence, characterization of the bioactivity of various 
graphene derivatives is very important so that we can develop graphene based materials and 
devices that have minimum risk of toxicity to living organisms and also so that these materials 
can be disposed and degraded effectively without causing any alteration to the ecological balance 
(Bussy et al. 2012).  
 Since its discovery and successful isolation, technology for the use of graphene and its 
derivatives is being developed actively (Chung et al. 2013). Due to its excellent properties, there 
is a growing interest in use of graphene based nanomaterials in biomedical devices. This means 
that the interaction of graphene with human cells and other living cells will increase with the 
increased use of this nanomaterial. This is the very reason which is driving the study of its 
biological activity as well. It is necessary to evaluate environmental risks of graphene-containing 
technological objects to biological systems (Akhaven 2010; Bussy et al. 2012). Studies so far 
have evaluated the effects of graphene on living cells, most importantly its effect on cell viability 
and proliferation. Graphene toxicity studies show that its number of layers, lateral size, stiffness, 
hydrophobicity, surface functionalization, and dose are important factors that determine its 
effects on cells (Adams and Jia 2005, Georgakilas et al. 2012, Katz and Hershberg 2013, Keseler 
et al. 2013). However, the toxicity and biocompatibility of graphene are debated (Bianco 2013). 
Evaluating the activity of graphene against bacteria is an important first step to understanding 
graphene’s bioactivity.  Prokaryotic model organisms provide the basis for understanding of 
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toxicity mechanisms of graphene on a simpler scale due to their relatively simple physiological 
manifestation (Efremova et al. 2015).  
In 2010, Akhavan and Ghaderi first described the toxic effect of graphene against several 
bacterial species and also showed that graphene oxide (produced through functionalization 
process) was more toxic to cells when compared to pristine graphene. Since then, the toxicity of 
different forms of graphene against bacteria has been studied extensively, but the results in these 
studies are somewhat contradictory. Most studies have used some form of functionalized 
graphene and compared the effects of functionalized graphene to the effects of pristine graphene 
on cells. In addition to the research on properties of functionalized graphene, there have been 
several studies that have linked the toxicity of graphene based materials on the presence of rough 
edges of graphene which cause physical damage to cells (Liu 2011).  
There have also been several studies that have looked at the interactions between 
graphene based nanoparticles and human tissues and cells. Most specifically, these studies have 
focused on the uptake and cellular response of macrophages to graphene nanoparticles and 
histopathological response to deposition of these nanoparticles (Liao et al. 2011; Bussy et al. 
2012). All studies that have been published so far have focused only on the cytotoxic effects of 
graphene.  
Previous unpublished work in our lab has characterized the cytotoxicity of oxidized 
graphene to Escherichia coli cells and the data suggests that concentrations greater than 160 
µg/ml of the functionalized graphene (FG) is toxic to E. coli. Cultures that were exposed to 
commercial graphene (CG), i.e., pristine graphene, at these concentrations, however, did not 
show decreases in cell density. This work served as the foundation for genotoxic analyses 
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described here as the graphene concentrations used in the present study were based on the above 
cytotoxicity analyses. 
Since there are no studies to date that investigate the effects of graphene on the DNA of 
cells we devised a novel approach to do so. The first step in this study was to evaluate the 
mutagenic potential of graphene by using Fluctuation Assay. Fluctuation Assay, also known as a 
Luria-Delbruck experiment, was first proposed and demonstrated by Nobel laureates Max 
Delbrück and Salvador Luria in 1943 (Luria and Delbrück, 1943). This assay was developed to 
assess the random nature of mutations that arise in a population of cells in the absence of any 
selection pressure. For these experiments, small numbers of cells are used to inoculate several 
parallel cultures (C) of bacteria that are grown to saturation in a non-selective growth medium. 
Several dilutions are then plated onto selective media (e.g. antibiotic containing media) to get an 
estimate of the number of mutants in each culture (r). Based on the number of mutants that grow 
on selective media, mutation rates can be estimated using several mathematical equations 
(described in the Results and Discussion chapter). Mutation rates are more reliable than merely 
calculating the frequency of mutants as mutation frequency varies greatly between the parallel 
cultures. This is because mutations are random in nature and the mutations that arise in earlier 
generations will be more prevalent than the mutations arising in later generations. To normalize 
for this variation, it is important to calculate mutation rate. The methods we have used for 
mutation rate calculation are based on either mean or median mutation frequency (see Results 
and Discussion section). 
Next, we assessed the nature of mutations that graphene exposure causes to the E. coli 
cells by sequencing the whole genome of representative rifampicin resistant mutants isolated in 
the Fluctuation Assay (Katz and Hershberg 2013). Mutations are changes in the DNA 
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sequencing that are inherited through generations. If a mutation causes an alteration in the amino 
acid sequence of protein then it is termed as nonsynonymous substitution and if the mutation 
does not produce any change in the protein sequence then these changes are called synonymous 
mutations. We used the Illumina MiSeq platform for sequencing the genomic DNA of these 
mutants.  MiSeq is a next-generation sequencing platform which produces reliable 
highthroughput data (Quail et al. 2012). Paired-end reads produced from a MiSeq sequencer 
were assembled to get the genome sequence of the mutants and parent, which were subsequently 
used to analyze the patterns of mutations. Preprocessing of the DNA sequence data was 
performed on Galaxy server (https://usegalaxy.org/) and the assemblies were generated and 
analyzed using software package DNASTAR (DNA Star Inc.). We then used EcoCyc and 
UniProt to understand the function of the genes that were affected by the mutations in the 
genome of the mutants. 
Lastly, we conducted growth analysis of the mutants (Davison et al. 2007, Wehrli 1983) 
to evaluate if the mutations confer any physiological advantage to E. coli cells for growth in 
presence of graphene.  
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MATERIALS AND METHODS 
 
Media and Culture Conditions 
The Escherichia coli strain used in this study is DH5 alpha [F- Φ80lacZΔM15 
Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rk-, mk+) phoA supE44 λ-thi-1 gyrA96 relA1]. 
The E. coli DH5 cells were revived from glycerol stocks by scraping off some cells from the 
frozen glycerol stock and streaking them on Luria-Bertani agar plate followed by incubating the 
plate at 37C for 12 hours. The liquid media used for culturing E. coli DH5 cells in this study is 
Luria-Bertani broth (Sezonov et al. 2007), which is a rich medium for E. coli growth. The 
composition of Luria-Bertani media per liter is 10.0 g Tryptone, 5.0 g Yeast extract, 5.0 g 
Sodium chloride. While performing Fluctuation Assay, Luria-Bertani broth was supplemented 
with 100 g/ml of Rifampicin. Rifampicin stock was prepared using the protocol suggested by 
Sambrook et al. (2012). Solid media used in the study was Luria-Bertani agar (Luria-Bertani 
broth + 10.0 g/L agar). Luria-Bertani agar was also supplemented with 100 g/ml Rifampicin, 
where appropriate. 
 
Graphene Source and Properties 
Graphene used in this study was provided by the Arkansas Research Alliance. From the 
dry graphene stock received, 2 mg each of either commercial (pristine) graphene (CG) or 
functionalized graphene (FG) were weighed and were resuspended in 1 ml double autoclaved 
water to make stock solutions of concentration 2 mg/ml. Final concentration of commercial and 
functionalized graphene used in the Fluctuation Assay experiments was 80 g/ml, so 120 l of 
the stock graphene solution was added to each 3 ml liquid culture.  
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 Fluctuation Assay 
We used Fluctuation Assay (Rosche and Foster, 2000) to estimate the frequencies of 
rifampicin resistance in E. coli DH5 cells in order to estimate the spontaneous mutation rates in 
E. coli DH5 cells. Fluctuation Assay was performed in two rounds using either shaken or 
unshaken cultures of E. coli. In the first round, we used ten parallel, shaken cultures of E. coli 
DH5 to estimate the intrinsic spontaneous mutation rate in the absence of any exposure to 
graphene. Briefly, ten each 14 ml culture tubes containing 5 ml Luria-Bertani broth were 
inoculated with ~1000 E. coli DH5 cells from a common starter culture. These ten parallel E. 
coli DH5 cultures were then incubated overnight at 37C with 250 rpm shaking. After 
incubation, 1 ml of culture was taken in a cuvette to measure the OD600 value using a 
spectrophotometer to quantitate the cell density of each culture. Out of the remaining 4 ml of 
culture, 100 l was spread directly on LB-agar plates containing Rifampicin, and 1 ml was 
concentrated 10-fold before being spread on LB-agar plates containing Rifampicin. For 
concentrating the cultures, 1 ml was taken from each of the ten culture tubes in ten 1.5 ml 
microcentrifuge tubes and centrifuged at 10,000 rpm at 23C for 10 minutes. 900 μl of 
supernatant was decanted from the microcentrifuge tube and the cell pellet was resuspended in 
the remaining 100 l broth in the tube by vortexing. These 10-fold concentrated cultures (100 l 
in volume) were spread on LB-agar plates containing Rifampicin. All 20 plates from this 
experiment were incubated at 37C for 36 hours before counting the number of colony forming 
units (CFUs) on each plate. 
In the second round of Fluctuation Assay, we set up 5 parallel, non-shaken cultures each 
for three different treatments. Fewer parallel cultures were used because the amount of graphene 
received was limited, and cultures were not shaken in order to minimize the shearing effects on 
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cells caused by graphene (Liu 2011). Cells were grown in 3 ml of either LB broth alone 
(control), LB broth containing 80 g/ml of commercial graphene (CG), or LB broth containing 
80 g/ml of functionalized graphene (FG). Five 14 ml culture tubes (per treatment) were 
inoculated with ~1000 E. coli cells from a common starter culture. The cultures were incubated 
for 14 hours at 37°C without shaking. After incubation, 100 l was spread directly on LB-agar 
plates containing Rifampicin, and also 1 ml from the culture was concentrated 10-fold before 
being spread on LB-agar plates containing Rifampicin. We spread three dilutions (10
-5
, 10
-6
, 10
-
7
) of the cultures on LB-agar plates to obtain an estimate of total viable cells per culture. We 
incubated these plates at 37°C for 12-36 hours. 
 After 12 hours of incubation, CFUs on the LB agar plates were counted to estimate the 
total number of viable cells per culture. After 36 hours of incubation, CFUs on the Rifampicin 
supplemented LB agar plates were counted to estimate the total number of Rifampicin resistant 
mutants. 
 
Mutation Frequency and Mutation Rate calculation 
Frequency of spontaneous mutations to Rifampicin resistance was estimated based on the 
second round of Fluctuation Assay by comparing the number of mutant colonies that grew on 
Rifampicin supplemented plates against the total number of cells in the culture (estimated based 
on the OD600 values). For estimating the mutation rate we used three independent methods 
described previously (Roshe and Foster, 2000), namely the Luria-Delbrück’s Method of the 
Mean (Luria and Delbrück 1943), the Lea-Coulson’s Method of the Median (Lea and Coulson 
1949) and, the Drake Formula using the median (Drake 19991).  
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Genomic DNA Isolation 
 We isolated genomic DNA (gDNA) from six representative rifampicin resistant E. coli 
mutants and the parent strain (WT) for sequencing using the Illumina MiSeq platform. Procedure 
for DNA isolation is described below. 
After growth on Rifampicin supplemented LB agar plates we randomly picked six 
individual colonies from independent plates for sequencing. Only one colony was picked from 
any given plate, and each colony originated from a different sample within each treatment. 
Genomic DNA extraction of each of these mutants was performed using Qiagen DNeasy Blood 
and Tissue Kit. Selected colonies were grown overnight in 5 ml LB broth supplemented with 
Rifampicin at 37°C with shaking at 250 rpm. The bacterial cells were then harvested by 
centrifuging the cultures for 10 minutes at 7500 rpm, supernatant was discarded and cell pellet 
was resuspended in 180 l enzymatic lysis buffer and incubated at 37C for 1 hour. The 
composition of the lysis buffer was 20 mM Tris-HCl, 2 mM Na-EDTA, 1.2% Triton X-100, and 
20 mg/ml of lysozyme from chicken egg white (Sigma-Aldrich). After 1 hour of incubation, 180 
l buffer ATL was added to the cell lyaste followed by addition of 20 l of proteinase K and 
then the tubes were incubated at 56°C for 30 minutes to ensure complete lysis of the bacterial 
cells. Following cell lysis, the tubes were briefly vortexed and 200 l of buffer AL was added to 
the samples and the samples were vortexed briefly. Then, 200 l of 99% ethanol was added to 
the samples followed by brief vortexing. The mixture was carefully transferred to DNeasy Mini 
spin column and centrifuged at 8000 rpm for 1 minute after which the flow-through was 
discarded. Buffer AW1 (500 l) was added to the column and the column was then centrifuged 
at 8000 rpm for 1 minute following with the flow-through was discarded along with the 
collection tube.  Spin column was placed in a new collection tube and 500 l of buffer AW2 was 
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added to the column. The column was centrifuged at 14,000 rpm for 3 minutes for the DNeasy 
membrane to dry. Flow-through was discarded along with the collection tube and the DNeasy 
Mini spin column was placed in a clean 1.5 ml Eppendorf tube and 50 l of pre-warmed Qiagen 
elution buffer water was added directly to the DNeasy membrane. The column was incubated for 
3 minutes at room temperature and then we centrifuged the column at 8000 rpm to elute the 
DNA. We repeated the elution step one more time by transferring the column to a clean 1.5 ml 
Eppendorf tube and adding 50 l of pre-warmed Qiagen elution buffer, incubating the column 
for 3 minute at room temperature, and then centrifuging the column at 8000 rpm to elute the 
DNA. 
For extraction of genomic DNA from E. coli DH5, the protocol described above was 
used with some minor modification; we used RNase treatment in the protocol since the initial 
gDNA preparations were contaminated with ribosomal RNA. We added 4 l of RNase A (100 
mg/ml) to the cell lysate and the microcentrifuge tube was incubated at room temperature for 2 
minutes which was followed by the addition of buffer AL (neutralization buffer) and ethanol. 
The DNA extraction steps following the RNase treatment were the same as described above. 
 
Genomic DNA Quantitation 
We used NanoDrop (Thermo Scientific) and Qubit assay (Thermo Fisher) to evaluate the 
quality of our genomic DNA samples and also to estimate the concentration of genomic DNA. 
For quantifying the genomic DNA, we used Qubit dsDNA BroadRange Assay kit (Life 
Technologies Inc). For each sample quantified, we diluted the assay reagent 200x in the buffer 
solution provided in assay kit. We also prepared Standards 1 and 2 from the assay kit to calibrate 
the Qubit fluorometer before quantifying the samples. As per manufacturer's protocol, 10 l each 
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of standard 1 and standard 2 were mixed with 190 l of diluted reagent in two Qubit assay tubes, 
followed by brief vortexing and centrifugation of these standard solutions. We then mixed 1 l 
of the genomic DNA into 199 l of diluted reagent in Qubit assay tubes and mixed the sample by 
vortexing the tubes briefly and then centrifuging the tubes briefly. The tubes were then incubated 
for 1 minute at room temperature before placing the tubes in Qubit fluorometer to get the 
concentration values of the sample. We used the ‘calculate stock concentration’ option on the 
fluorometer to get the total concentration of the sample. We used NanoDrop to get Abs260/Abs280 
ratio of the samples so we could be sure that the samples were free of contamination from 
proteins. In doing so, we used 1l from each of the sample and measured its absorbance using 
NanoDrop. 
 
Agarose Gel Electrophoresis 
We separated 1 l of each of the rifampicin mutant genomic DNA samples and 5 l of E. 
coli DH5 genomic DNA sample on an agarose gel to check the quality of extracted genomic 
DNA. Agarose gel (1% concentration) was prepared by dissolving 0.5 g agarose in 50 ml 0.5X 
TBE buffer by heating in a microwave for 1 minute. The liquid agarose gel was then allowed to 
cool for 5 minutes before adding 5 l SYBR Safe DNA gel stain and the liquid agarose gel was 
poured in gel tray with the well comb in place and was left for 30 minutes for solidifying. After 
30 minutes, the well comb was removed and the gel was transferred to electrophoresis chamber 
filled with 0.5X TBE and samples were loaded in gel wells. We ran the gel at 80V for 90 
minutes. DNA imaging protocol for SYBR safe (ThermoFisher Scientific) was used on a Bio-
Rad Molecular Imager Gel Doc (Bio-Rad) to visualize DNA. 
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Genome Sequencing 
After checking the quality and quantity of purified genomic DNA from the six 
Rifampicin resistant mutants (3 mutants from commercial graphene (CG) treatment and 3 
mutants from functionalized graphene (FG) treatment) and the E. coli DH5 genomic DNA, we 
provided approx. 250 ng of genomic DNA of each sample to the UAMS DNA Sequencing Core 
Facility for shotgun whole genome sequencing. The gDNA samples were sequenced on Illumina 
MiSeq platform. DNA samples from the six mutants were bar coded and pooled together prior to 
being run on a single MiSeq cartridge. A total of 23,346,132 paired-end reads (2 x 250 bp) were 
obtained for the six pooled mutant genomes, and 33,857,684 paired-end reads (2 x 250 bp) were 
obtained for E. coli DH5 gDNA, which was sequenced separately to obtain a higher coverage 
reference sequence. 
 
Sequence Data Preprocessing 
The Fastq sequence read files obtained from the sequencing facility were uploaded on 
Galaxy server (https://usegalaxy.org/). Fastq files were first groomed using FASTQ groomer 
package followed by trimming of low quality reads using FASTQ quality trimmer package. 
Sequences with a quality score less than 30 were trimmed from 5’ and 3’ ends using sliding 
window (Window size 1, Step size 1), as well as reads with zero length were excluded from the 
files. Quality of filtered and trimmed reads was assessed through FASTQC and the sequence 
read files were then downloaded for subsequent analyses. 
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Genome Sequence Analysis 
After downloading the filtered and trimmed read files, the two files containing the left 
and right paired-end sequences were concatenated in one file. After this step, we had 7 files, one 
each for the six mutants and one for the parent strain. The genome of E. coli strain K-12 
MG1655 was downloaded from NCBI and was used as template for assembly of all seven 
genomes. The reads were first assembled using SeqMan NGen software (DNAStar, Inc.) using 
the Templated Assembly Workflow using E. coli strain K-12 MG1655 as template. High SNP 
Filter stringency was used while assembling the reads. 
For each assembly generated through SeqMan NGen, SNP reports were created using 
SeqMan Pro. SNPs were filtered using High SNP Filter stringency (%SNP >= 75% and coverage 
depth >= 40). After filtering out the ambiguous SNPs, the remaining SNPs were confirmed and 
exported as tab delimited files. We compared the nucleotide changes between the parent strain 
(WT) and the rifampicin resistant mutants. Downstream analyses of these SNPs were done 
manually by comparing the position of nucleotide change in reference sequence and nucleotide 
change occurring at each position in the mutants. We used EcoCyc (Keseler et al.) and UniProt 
(UniProt Consortium 2015) to find the SNP containing genes and to find the pathways that these 
genes are involved in. 
 
Growth Analysis of Mutants 
 We performed growth analysis (Davison et al. 2007, Wehrli 1983) of the rifampicin 
resistant mutants that were isolated from Fluctuation Assay performed in the presence of 
graphene in the growth medium. For doing so, we revived glycerol stocks of two CG and two FG 
mutants on LB-agar plates containing rifampicin (100 µg/ml). We used the parent E. coli DH5α 
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as the control (wildtype, WT) for this experiment which was revived on LB-agar plates. We then 
picked a single colony from each plate and inoculated starter culture. For wildtype E. coli DH5α 
we used 2 ml LB as growth medium, whereas 2 ml LB broth supplemented with rifampicin (100 
µg/ml) was used for growth of CG and FG mutants. All culture tubes were incubated for 12 
hours at 37°C with 250 rpm shaking. OD600 for each culture was measured for each culture after 
incubation. The cell density for each culture was estimated. Approximately 10
6
 cells from each 
culture of the mutants and wildtype E. coli DH5α were used to inoculate LB broth 
(supplemented with rifampicin for CG and FG mutants) in a 96-well plate. Commercial graphene 
(CG) or functionalized graphene (FG) was added at concentrations 0 µg/ml (control), 80 µg/ml, 
or 320 µg/ml. The 96-well plate was then incubated at 37°C for 6 hours. Following incubation, 
dilution plates were made for each treatment using LB broth as medium with seven successive 
10-fold dilutions. From these dilution plates, 10
-3
, 10
-4
, 10
-5
, 10
-6
, and 10
-7
 dilutions were plated 
on LB agar plates and the plates were incubated at 37°C for 14 hours before counting the number 
of colony forming units (CFUs) on each plate in order to estimate the number of viable cells in 
each treatment. 
  
 15 
 
RESULTS AND DISCUSSION 
 
Frequency of spontaneous mutations to rifampicin resistance in E. coli 
 To estimate the intrinsic rate of spontaneous mutations to rifampicin resistance in E. coli 
DH5α cells we set up Fluctuation Assay (Rosche and Foster 2000) with 10 parallel, shaken 
cultures. Cultures were grown in LB broth for 12 hours. Cell density was measured using OD600 
and cell count was estimated using an online calculator 
(http://www.genomics.agilent.com/biocalculators/calcODBacterial.jsp). A complete list of OD600 
values and the corresponding cell densities is given in Table I.  As seen from the data, the OD600 
values ranged from 1.099, which corresponds to about 8.79x10
8 
cells/ml, to 1.237, which 
corresponds to about
 
9.9x10
8
 cells/ml. 
 To determine the frequency of spontaneous mutations to rifampicin resistance (Rif
R
), 
aliquots from each culture were plated on LB-agar plates supplemented with rifampicin. The 
numbers of Rif
R
 colonies per culture are given in Table II. From this experiment we estimated 
that the frequency of spontaneous mutations to rifampicin resistance (Rif
R
) in our Fluctuation 
Assay cultures was about 4.76 (± 2.71 standard deviations) mutants per 10
8 
cells. Frequency of 
spontaneous mutations to rifampicin resistance has been previously reported to be 2.6 x10
-8
 in E. 
coli strain K12 MG1655 (Katz and Hershberg, 2013) which is comparable to the mutation 
frequency we observe in our experiment. The Rif
R
 frequency we determined through this 
preliminary experiment helped us plan the following experiment as the Rif
R
 frequency was 
neither too high nor too low for a 5 ml culture volume to be used in our subsequent Fluctuation 
Assay. 
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Effect of graphene exposure on the rate of spontaneous mutations to rifampicin resistance 
in E. coli 
 In order to estimate the rate of spontaneous mutations to rifampicin resistance in E. coli 
cells upon exposure to graphene, we performed the Fluctuation Assay with five parallel cultures 
containing either commercial graphene (CG) or functionalized graphene (FG) or no graphene 
(control). Table III lists the number of colonies formed on each plate and the cell number 
calculated based on the number of colony forming units (CFUs) on plates. We estimated cell 
numbers in each culture by counting the colonies on LB agar plate as we could not measure the 
OD600 for cultures containing graphene. We could not rely on OD600 values for these cultures as 
graphene particles in media would interfere with measurement of the optical density of cultures. 
We excluded the cultures where no colonies grew on rifampicin plates from these analyses 
(indicated as No Data (ND) in Table IV). We estimated average cell number in the cultures 
grown in LB broth, LB broth containing commercial graphene, and LB broth containing 
functionalized graphene. The cultures that were grown in the presence of graphene (either 
commercial or functionalized) on average have 5 times less cells than the cultures grown in LB 
broth without graphene. The cell number in the previous experiment (Fluctuation Assay in the 
absence of graphene) was higher than in this experiment as the culture growth conditions 
(shaking vs. non-shaking, respectively) were different between the two experiments. Cultures 
tubes were incubated without shaking to prevent any potential physical damage to cells by the 
rough edges of graphene (Liu 2011). 
 From this experiment, we estimated the frequency of Rif
R
 mutations (Table IV). The Rif
R
 
frequency was found to be around 3.98 mutants per 10
8
 cells in the control (LB alone). The 
commercial graphene (CG) and functionalized graphene (FG) treatment had Rif
R
 frequencies of 
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3.93 and 8.74 per 10
8
 cells, respectively. These data indicate an increase in the frequency of Rif
R
 
mutants in cultures exposed to functionalized graphene. The value of Rif
R
 in CG treatment is 
comparable to that of LB alone (control). On the other hand, in FG treatment, the Rif
R
 frequency 
is 2-fold higher than that of control (LB alone) or CG treatments.  
 After determining the frequency of Rif
R
 mutations, we wanted to calculate the mutation 
rate under each treatment. For calculating the mutation rate for each treatment (LB control, CG, 
and FG) we used three methods; the Luria- Delbrück (Luria and Delbrück 1943) method of the 
mean (r=m ln(mC)), the Lea-Coulson (Lea and Coulson 1949) method of the median ((r/m) –
ln(m) = 1.24), and the Drake (Drake 19991) formula ((r/m) – ln(m) = 0). In these equations, r is 
the observed number of mutants in a culture, C is the number of cultures in the experiment, and 
m is the number of mutants per culture. The values for mutation rates calculated using these 
methods are given in Table V. As the data suggests, all three methods give us a different value 
for the mutation rate but if we compare the three mutation rates values for each treatment we see 
that there is an increase in the mutation rate in cultures exposed to functionalized graphene. The 
mutation rate values for CG treatment was higher than the untreated control (LB) when Luria- 
Delbrück method of the mean was used to calculate mutation rate, but lower when we used the 
methods of median (Lea-Coulson and Drake formula). This could be due to the fact that data was 
available for only three CG-treated cultures (see Table IV), which may have skewed the 
calculation of the mean. Mutation rate values for FG treatment were higher than for either 
control (LB alone) or CG treatment regardless of the mutation rate calculation method used. The 
increased mutation rate values for FG treatment suggests that functionalized graphene is 
genotoxic to E. coli. 
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Whole genome sequencing and analysis of E. coli mutants and parent (WT)  
 After determining the mutation rates for cells grown in the presence of graphene, we 
wanted to investigate the nature of mutations in the genomic DNA of mutants obtained in the 
presence of CG or FG treatment. For this, we sequenced the genomic DNA of random Rif
R
 
mutants. We picked a total of six Rif
R
 mutant colonies, three each from CG and FG treatments. 
These mutants were grown overnight in LB broth supplemented with Rifampicin and genomic 
DNA was extracted using Qiagen DNeasy blood and tissue kit. To assess the quality of the 
samples, 1 µL from each genomic DNA sample was run on agarose gel (Figure 1). For 
comparing the size of extracted genomic DNA, we ran all samples against 1 kb ladder from NEB 
with a range of 10,000 bp-500 bp. All samples ran as a single band >10,000 kb without any 
smear or accessory band which indicates that the extracted genomic DNA was of high quality. 
We then quantitated the samples using Qubit BR DNA assay and NanoDrop. Concentration and 
Abs260/Abs280 ratios for each sample is given in Table VI. Values of Abs260/Abs280 ratio of 
between 1.8-2.0 are indicative of pure DNA that is free of protein contamination. Approximately 
250 ng from each sample was then sent for sequencing on Illumina MiSeq at UAMS DNA 
sequencing facility. 
 We also sequenced the parent strain in order to get more reliable insight on the changes in 
DNA that may have been caused by graphene exposure. We extracted genomic DNA from 
parent (WT) cells and sent approx. 250 ng to UAMS DNA sequencing facility for Illumina 
MiSeq sequencing. Qubit concentration and Abs260/Abs280 ratio obtained from Nanodrop for the 
WT sample are given in Table VI. Figure 2 is the agarose gel image of the 5 µL of genomic 
DNA ran against 1 kb ladder. The WT gDNA ran as single band >10,000 kb which confirms the 
quality of DNA extracted. For sequencing we used DNA from first elution as labeled in Figure 2. 
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 Sequence reads that we acquired were first processed on Galaxy server 
(https://usegalaxy.org/) and after filtering out the low quality reads we imported the sequence 
reads in DNASTAR software (DNAStar, Inc.). A summary of reads from Illumina MiSeq 
NextGen sequencing is shown in Table VII. The paired-end reads for each mutant sample were 
aligned to the reference E. coli genome K-12 MG1655 and the reads assembled into a single 
contig of 4,639,675 bp without gaps which is the same length as the reference genome. The 
length of each contig with gaps along with the median coverage values for each contig is listed in 
Table VIII. All assembled contigs had N50 value of 4641k. 
 Sequence reads of the genomic DNA of the parent strain (WT) were also processed and 
assembled in the exact same way. Table VII lists the number of reads for the sample and the 
number of low quality reads that were filtered out using the Galaxy server. The number of reads 
and coverage for the parent strain were substantially higher than those of the mutants as the six 
mutant samples were multiplexed whereas the parent strain was not. The median coverage and 
contig length for parent strain are listed in Table VIII. 
 We used SeqManPro in the DNASTAR software to generate SNP reports for each of the 
seven assembled genomes (parent and six mutants). From the SNP reports generated we 
identified SNPs using very high stringency parameters, namely read depth of 40 or higher and 
%SNP of 75% or higher. SNPs with low coverage score were rejected from further analysis. 
Numbers of SNPs for each genome are given in Table IX and the number of shared/unique SNPs 
is represented in a Venn diagram in Figure 3. A total of 22 mutations were common across all six 
mutant genomes. In addition to the shared mutations, there are changes that are exclusive to 
either CG or FG mutants which are shown in Figure 4. There are two mutations that are shared 
within the three CG mutants and one mutation that is shared within the three FG mutants. 
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 Among the 22 mutations shared by all six mutants, 6 mutations were synonymous 
(Henaut and Danchin 1996), i.e. these mutations do not cause changes in the amino acid 
sequence of the protein, 6 mutations were found in non-coding portions of the genome, 3 of these 
mutations occurred in the rRNA gene sequences. The non-synonymous mutations (Henaut and 
Danchin 1996) were found in genes insB (insertion element), lacZ (part of lac operon which 
hydrolyses lactose to galactose and glucose), mhpD (calalyzes conversion of 2-
hydroxypentadienoic acid to 4-hydroxy-2-ketopentanoic acid), ymfE (uncharacterized membrane 
protein), and wbbK (putative glycosyltransferase, part of outer membrane biogenesis). We could 
not find any evidence from literature on the association between these genes and bacterial stress 
response.  
 The mutations that are not shared by all six mutants are given in Table X. The table has 
information about the mutants which have the mutation, position of nucleotide change, 
nucleotide base change, and the gene which has that mutation. There are 4 different non-
synonymous mutations in the rpoB gene. Mutations in rpoB gene are known to confer resistance 
to Rifampicin (Reynolds 2000). Gene yghO also contains a non-synonymous mutation and this 
gene is involved in biofilm production (Beloin et al. 2004). The other two non-synonymous 
changes are present in the promoter regions of genes fixA and yhhW. Gene fixA is predicted to 
play a role in electron transport in E. coli (Eichler et al. 1995) and gene yhhW is proposed to be 
involved in a mechanism that prevents inhibition of DNA gyrase by quercetin (Adams and Jia 
2005). None of these genes, however, have previously been shown to be directly involved in 
pathways related to stress response in E. coli.  
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Functional characterization of genomic mutations induced by graphene exposure 
 We performed growth analysis (Davison et al. 2007, Wehrli 1983) of the FG and CG 
mutants from Fluctuation Assay to assess whether mutations towards rifampicin confers any 
selective advantage to these mutants when compared to wildtype E. coli DH5α cells. We picked 
two CG and two FG mutants (which we had already sequenced) for this test and included 
wildtype E. coli DH5α cells as control. Each strain was revived from frozen glycerol stocks on 
LB agar plates and then grown in liquid medium to be used in the experiment. CG and FG 
mutants were grown in medium supplemented with rifampicin and the wildtype cells were grown 
in non-selective media. OD600 values were measured and cell densities of the cultures were 
estimated (Table XI) to ensure each treatment has comparable number of cells at the beginning 
of experiment. The CG, FG mutants and the wildtype cells were each exposed to either 
commercial or functional graphene at concentrations 0 µg/ml (control), 80 µg/ml, and 320 µg/ml. 
After incubation, five dilutions (10
-3
, 10
-4
,10
-5
, 10
-6
, and 10
-7
) from each treatment were spread 
on LB agar plates to estimate the number of viable cells in each culture. 
 Plates where 10
-3
 and 10
-4
 dilutions were plated had a lawn of bacteria in each treatment, 
and therefore it was not possible to get a cell count from these dilutions. Table XII contains the 
cell count for all the other dilutions. Mutant FG1 dilution plates had lawns even on the 10
-5
, 10
-6
, 
and 10
-7 
dilutions and hence that data has been marked as TNTC (too many to count) in the table. 
Based on the number of colony forming units on each plate, we calculated the average number of 
viable cells. The average cell density for CG1 and CG2 mutants, FG2 mutant, and WT E. coli 
DH5α cells is represented in Figure 5 along with the standard error bars. 
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 Since these mutants were originally obtained upon exposure of E. coli to commercial or 
functionalized graphene at concentration 80 µg/ml, we expected that CG mutants will have 
higher viability when re-exposed to commercial graphene at this concentration and FG mutants 
will have higher viability when re-exposed to 80 µg/ml of functionalized graphene. 
Results from the CG mutants did not show a consistent trend. CG2 grew better in the 
presence of either commercial or functionalized graphene compared to the control. CG1 grew 
slightly better in the presence of commercial and functionalized graphene compared to control, 
except at 80 µg/ml of functionalized graphene. FG2 also showed better growth in the presence of 
commercial graphene, but not in the presence of functionalized graphene, compared to the 
control. From previous work in our lab, we know that functionalized graphene is cytotoxic to 
WT E. coli DH5α cells. Data from the WT cultures are in general agreement with our previous 
data. However, data obtained for WT exposed to 320 µg/ml of functionalized graphene was 
surprising and may represent an error in data acquisition in this study. Additional experiments 
are needed to clarify if the mutations isolated from graphene exposure confer any physiological 
advantage to E. coli. 
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CONCLUSION 
 This study used a novel approach to study the genotoxic effects of graphene on the E. coli 
genome. By performing Fluctuation Assay we calculated and compared the rate of mutation to 
rifampicin resistance (Rif
R
) in the presence and absence of graphene. From this experiment we 
concluded that there is an increase in Rif
R
 mutation rate when cells are exposed to functionalized 
graphene. We then selected and sequenced the genomes six Rif
R 
mutants from Fluctuation Assay 
to analyze mutations in the genomes of the mutants. Using very high stringency parameters, we 
discovered 25-27 nucleotide changes in the genomes of the mutants when compared to the parent 
out of which 22 changes were shared by all mutants. This was very interesting as these mutants 
came from different plates, samples, and treatments. If mutations were truly random we would 
not have seen the same position and nucleotide change in all six mutants. Finally, since the 
mutations arose in the presence of either commercial or functionalized graphene, we wanted to 
test if the mutants had any growth advantage in the presence of either graphene. Results from 
this experiment revealed that in general, all mutants grew better in the presence of commercial 
graphene compared to the control, while only the CG mutants grew better in the presence of 
functionalized graphene compared to control. Additional experiments are needed to understand 
the physiological relevance of these mutations in E. coli. 
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Tables and Figures 
Table I 
OD600 and cell density values for ten untreated, shaken cultures of E. coli used for Fluctuation 
Assay  
Culture number OD600 values after 12 hours Estimated cell density (per ml) 
1 1.099 8.79 x10
8
 
2 1.156 9.25 x10
8
 
3 1.133 9.06 x10
8
 
4 1.195 9.56 x10
8
 
5 1.131 9.05 x10
8
 
6 1.115 8.92 x10
8
 
7 1.14 9.12 x10
8
 
8 1.129 9.03 x10
8
 
9 1.237 9.9 x10
8
 
10 1.158 9.26 x10
8
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Table II 
Calculation of the frequency of spontaneous mutations to rifampicin resistance (Rif
R
) in 
untreated, shaken cultures of E. coli 
Culture 
number 
Number of 
colonies on 
Rif plates 
(100 μl) 
Number of 
colonies on 
Rif plates 
(100 μl) x10 
Number of 
colonies on 
Rif plates 
(1ml) 
Average 
number of 
Rif
R
 
mutants 
Estimated 
cell 
density 
(per ml) 
Rif
R
 
frequency 
per 10
8 
cells 
1 3 30 127 78.5 8.79 x10
8
 8.93 
2 1 10 61 35.5 9.25 x10
8
 3.84 
3 2 20 26 23 9.06 x10
8
 2.54 
4 1 10 18 14 9.56 x10
8
 1.46 
5 1 10 22 16 9.05 x10
8
 1.77 
6 2 20 73 46.5 8.92 x10
8
 5.21 
7 3 30 93 61.5 9.12 x10
8
 6.74 
8 2 20 49 34.5 9.03 x10
8
 3.82 
9 ND ND 43 43 9.9 x10
8
 4.34 
10 ND ND 83 83 9.26 x10
8
 8.96 
Average Rif
R
 mutation frequency per 10
8
 cells 4.76 
Standard deviation 2.71 
Note: ND (no data) indicates that no colonies grew on the corresponding plate. 
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Table III 
Cell density values for five treated, non-shaken cultures of E. coli used for Fluctuation Assay 
Culture 
number 
Number of colonies 
on LB-agar plates 
(10
-5 
dilution) 
Number of colonies 
on LB-agar plates 
(10
-6 
dilution) 
Number of colonies 
on LB-agar plates 
(10
-7 
dilution) 
Cell density 
per culture 
LB1 TNTC 215 23 2.23 x10
8
 
LB2 TNTC 153 37 2.62 x10
8
 
LB3 TNTC 197 35 2.74 x10
8
 
LB4 TNTC 235 36 2.98 x10
8
 
LB5 TNTC 328 96 6.44 x10
8
 
Average cell density for LB cultures 3.40 x10
8
 
CG1 612 48 2 0.43 x10
8
 
CG2 564 54 7 0.60 x10
8
 
CG3 572 53 8 0.63 x10
8
 
CG4 556 63 2 0.46 x10
8
 
CG5 456 57 4 0.48 x10
8
 
Average cell density for CG-treated cultures 0.52 x10
8
 
FG1 656 50 7 0.62 x10
8
 
FG2 560 72 3 0.53 x10
8
 
FG3 724 62 6 0.65 x10
8
 
FG4 372 59 9 0.62 x10
8
 
FG5 592 59 11 0.76 x10
8
 
Average cell density for FG-treated cultures 0.63 x10
8
 
Note: TNTC (too many to count) indicates that there was a bacterial lawn on the corresponding 
plate. LB indicates control (untreated) cultures; CG indicates CG-treated cultures; FG indicates 
FG-treated cultures of E. coli. 
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Table IV 
Calculation of the frequency of spontaneous mutations to rifampicin resistance (Rif
R
) in treated, 
non-shaken cultures of E. coli 
Culture 
number 
Number of 
colonies on Rif 
plates (100μl) 
Number of 
colonies on Rif 
plates (100μl) 
x10 
Number of 
colonies on Rif 
plates (1ml) 
Average 
number of 
Rif
R
 mutants 
Rif
R
 
frequency per 
10
8
 cell 
LB1 1 10 9 9.5 4.27 
LB2 2 20 19 19.5 7.46 
LB3 ND ND 3 3 1.10 
LB4 ND ND 4 4 1.34 
LB5 4 40 34 37 5.75 
Average Rif
R
 mutation frequency for LB cultures 3.98 
CG1 ND ND ND ND ND 
CG2 ND ND 3 3 2.78 
 CG3 ND ND ND ND ND 
CG4 ND ND 2 2 3.12 
CG5 ND ND 4 4 5.89 
Average Rif
R
 mutation frequency for CG-treated cultures 3.93 
FG1 ND ND 1 1 0.87 
FG2 ND ND 2 2 2.41 
FG3 2 20 6 13 10.32 
FG4 1 10 7 8.5 7.35 
FG5 5 50 29 39.5 22.76 
Average Rif
R
 mutation frequency for FG-treated cultures 8.74 
Note: ND, no data was available as no colonies grew on the corresponding plate. LB indicates 
control (untreated) cultures; CG indicates CG-treated cultures; FG indicates FG-treated cultures 
of E. coli.  
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Table V 
Calculation of the rate of spontaneous mutations to rifampicin resistance in treated, non-shaken 
cultures of E. coli 
Treatment LD mean LC median Drake formula 
Control (LB alone) 1.807 2.122 3.164 
CG exposure 2.134 1.737 3.097 
FG exposure 3.448 2.915 4.729 
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Table VI 
Concentration and Abs260/Abs280 ratio of genomic DNA extracted from Rif
R
 mutants and parent 
(WT) 
Sample Concentration (ng/µl) A260/A280 ratio 
CG1 72.8 1.80 
CG2 72.2 1.82 
CG3 61.6 1.96 
FG4 98.6 1.77 
FG5 40.2 1.78 
FG6 52.2 1.99 
WT 44.2 1.97 
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Table VII 
Summary of reads from Illumina MiSeq NextGen sequencing of the E. coli genomic DNA 
Sample 
Total reads 
obtained 
Low-quality reads 
(filtered out) 
Final number of high-quality reads used for 
genome assembly 
CG1 4,754,534 1,444 4,753,090 
CG2 3,445,746 771 3,444,975 
CG3 4,564,014 2,658 4,561,356 
FG4 4,239,402 1,120 4,238,282 
FG5 3,504,652 622 3,504,030 
FG6 2,837,784 2,705 2,835,079 
WT 33,857,684 27,893 33,829,791 
 
  
 35 
 
Table VIII 
Summary of genome assembly statistics using DNASTAR software 
Sample Contig length with gaps Median coverage 
CG1 4,640,974 213.30 
CG2 4,640,676 166.28 
CG3 4,641,042 200.99 
FG4 4,641,046 203.28 
FG5 4,640,972 175.00 
FG6 4,640,599 136.92 
WT 4,645,702 1411 
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Table IX 
Number of nucleotide mutations in each genome 
Sample 
Number of 
nucleotide 
mutations  
CG1 25 
CG2 27 
CG3 27 
FG4 25 
FG5 27 
FG6 27 
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Table X 
Summary of nucleotide mutations not shared by all mutants 
Mutant Nucleotide 
position 
Nucleotide change Gene or region 
CG1,CG2,CG3,FG4,FG5 42108 A>G fixA promoter 
CG3,FG5,FG6 2302544 GG>TC  
FG6 3128183 G>A yghO 
CG2 3205570 G>- ttdB 
FG4,FG5,FG6 3579873 A>G yhhw promoter 
CG2,CG3 3742392 T>C yiaM 
FG5 3939897 C>T rRNA 
CG1,CG2,CG3,FG5,FG6 4169804 G>A rRNA 
CG1,FG6 4179710 A>C rpoB 
CG2,CG3 4180852 C>T rpoB 
FG5 4180954 A>C rpoB 
FG4 4180981 A>C rpoB 
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Table XI 
OD600 values of the cultures of E. coli mutants used for growth analysis 
Sample OD600 Cell density 
CG1 1.327  1.06 x10
9
 
CG2 1.355  1.08 x10
9
 
FG1 0.813  6.5 x10
8
 
FG2 1.196 9.57 x10
8
 
WT 1.456  1.16 x10
9
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Table XII 
Number of colony forming units (CFUs) on dilution plates for growth analysis 
Sample 
 
Graphene 
conc. 
(µg/ml) 
Commercial Graphene Functionalized graphene 
10
-5
 
dilution 
10
-6
 
dilution 
10
-7
 
dilution 
10
-5
 
dilution 
10
-6
 
dilution 
10
-7
 
dilution 
CG1 0 67  46  6  624  24  6 
80 880  59  4  528  53  1  
320 368  69  6  444  100  7 
 
CG2 0 376  48  8  336  52  7 
80 724  81  9  788  52  8  
320 784  114  7  534  81  11  
 
FG1 0  
TNTC 
 
TNTC 
 
TNTC 
 
TNTC 
 
TNTC 
 
TNTC 80 
320 
 
FG2 0 178  24  4  406  55  11 
80 556  61  4  894  94  7 
320 508  33  5  702  90  8  
 
WT 0 250  58  3  212  26  4  
80 430  57  3  228  35  1 
320 328  40  8  296  44  5  
 
Note: TNTC (too many to count) indicates that there was a bacterial lawn on the corresponding 
plate. 
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Figure 1 
Agarose gel electrophoresis of genomic DNA isolated from CG and FG mutants for genome 
sequencing 
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Figure 2 
Agarose gel electrophoresis of genomic DNA isolated from E. coli DH5α for genome 
sequencing 
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Figure 3 
Analysis of shared and unique mutations in the genomes of CG and FG mutants 
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Figure 4 
Analysis of shared and unique mutations within the genomes of either CG or FG mutants 
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Figure 5 
Effect of graphene on the growth of CG and FG mutants as well as parent (WT) 
 
 
 
 45 
 
 
 
 
